Targeting Abeta and tau in Alzheimer's disease, an early interim report
about
Gpr3 stimulates Aβ production via interactions with APP and β-arrestin2Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.γ-Secretase inhibitors and modulators.Protective Effects of Dietary Supplementation with a Combination of Nutrients in a Transgenic Mouse Model of Alzheimer's DiseaseNeuroRDF: semantic integration of highly curated data to prioritize biomarker candidates in Alzheimer's diseaseAnimal models for Alzheimer's disease and frontotemporal dementia: a perspectiveRobust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapyLigand-based and structure-based investigation for Alzheimer's disease from traditional chinese medicine.Alum and squalene-oil-in-water emulsion enhance the titer and avidity of anti-Aβ antibodies induced by multimeric protein antigen (1-11)E2, preserving the Igg1-skewed isotype distributionAnti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shiftModeling of age-dependent amyloid accumulation and γ-secretase inhibition of soluble and insoluble Aβ in a transgenic mouse model of amyloid deposition.Advances with RNA interference in Alzheimer's disease research.Apolipoprotein E in synaptic plasticity and Alzheimer's disease: potential cellular and molecular mechanisms.Tools of the trade: investigations into design strategies of small molecules to target components in Alzheimer's disease.OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE.Evolution of neurodegeneration.Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathologyRetention in endoplasmic reticulum 1 (RER1) modulates amyloid-β (Aβ) production by altering trafficking of γ-secretase and amyloid precursor protein (APP).Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's diseaseGeneration of a new transgenic mouse model for assessment of tau gene silencing therapies.Rapamycin inhibits lipopolysaccharide-induced neuroinflammation in vitro and in vivo.Identification and biology of α-secretase.Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer's disease.Molecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Active immunotherapy options for Alzheimer's disease.Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.Complex relationships between substrate sequence and sensitivity to alterations in γ-secretase processivity induced by γ-secretase modulatorsNGP 555, a γ-Secretase Modulator, Lowers the Amyloid Biomarker, Aβ42, in Cerebrospinal Fluid while Preventing Alzheimer's Disease Cognitive Decline in Rodents.Inflammatory Cytokines and Alzheimer's Disease: A Review from the Perspective of Genetic Polymorphisms.Dianxianning improved amyloid β-induced pathological characteristics partially through DAF-2/DAF-16 insulin like pathway in transgenic C. elegans.Combination of Aβ Suppression and Innate Immune Activation in the Brain Significantly Attenuates Amyloid Plaque Deposition.From a mouse: systematic analysis reveals limitations of experiments testing interventions in Alzheimer's disease mouse models.Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin-D detection.Secretory sorting receptors carboxypeptidase E and secretogranin III in amyloid β-associated neural degeneration in Alzheimer's disease.
P2860
Q24337284-876F11BF-5ABB-490B-8A65-7B12666196A6Q24624879-9220AB02-11E3-4D84-8499-8DCAF67E5A3CQ26830462-7F8302F3-A325-43A7-AB7D-7984287FAB85Q28551173-AD9101E8-B6E3-4491-B1B8-E7D1FEE27290Q28596503-B60E8BBF-B074-49BD-97E9-FED4CF4FEF69Q28749702-4F1E59BF-79C8-40CD-9B1B-1437EBE06398Q30499456-3268AB0F-759B-418B-818B-E5845E9C9664Q33668480-BE93DB09-0BD9-492E-9270-F808C2F5B64DQ33831036-65A550CA-8734-4DB7-BAD3-A0AD81ED1ED5Q34160589-58ABC7A2-8032-4085-AB97-2650F29A793EQ34292546-2CB72DF4-D23D-43E2-97E1-4FB389127F24Q34330911-AF713ED8-5144-445D-8C50-6D9E25B10913Q34628212-F53CA2E0-1AF3-438A-A15F-6422F1A1DB19Q35577737-0F6ADD44-ACC7-4895-B368-B66E09A37F5EQ36221014-FFC4183B-B012-40EA-BB80-AF4738D3BE45Q36325667-59F9A526-E547-47DD-97BF-6C684DB20380Q36335011-6805097C-55CE-46D3-A9BD-62303F4663A2Q36418911-005849A2-76E2-4D28-B48B-14E96356AB6DQ37190538-4756CB9D-D3D2-4BA4-8396-0B4C8A577996Q37232081-4A67DCA7-9943-492D-BE79-5250D2C8935CQ37707528-F35B785D-07AB-451B-9EFD-298BEA08DD7AQ37961730-1D33213A-B3D1-40B4-8E52-85B8ABFC910FQ37984574-1A4387C5-5268-4CB6-A058-FE50F2C6AFD7Q38062334-D670398D-5966-47BF-AEBC-B0892A84C678Q38086422-C1FF6D6E-89A0-4B51-B45D-1F9FEAD7E8DEQ38127470-25D4BA7D-B7B8-4F42-8074-2ABC563AF812Q38183140-F9D22F3D-67DD-4DF9-9ECF-1A5A54E78886Q38203031-DDF0D772-8674-48A6-A5FD-E4824C4DB638Q38737649-DA43A20C-B678-42F4-B988-34749C0E4444Q38790207-9C76EF23-EB80-484C-99A1-493C27342BB5Q38938968-F83D09B8-0277-487F-806F-8542E64FE73DQ41199961-5B163816-7B43-4046-97CD-F6247EDB8020Q41935920-EC93E55E-15DE-408E-BA84-610B5462B0C3Q47103043-903C3CFB-8D51-4B17-AA63-038D4FBCA1DFQ47783009-6F800E55-221C-4731-8AAE-C45AFBE34C7EQ48229419-138259A3-B613-48EF-98EF-1A39542BCBC3Q48368176-C93B9B14-3EBB-4F41-B0F7-12A0A47898F7
P2860
Targeting Abeta and tau in Alzheimer's disease, an early interim report
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Targeting Abeta and tau in Alzheimer's disease, an early interim report
@ast
Targeting Abeta and tau in Alzheimer's disease, an early interim report
@en
type
label
Targeting Abeta and tau in Alzheimer's disease, an early interim report
@ast
Targeting Abeta and tau in Alzheimer's disease, an early interim report
@en
prefLabel
Targeting Abeta and tau in Alzheimer's disease, an early interim report
@ast
Targeting Abeta and tau in Alzheimer's disease, an early interim report
@en
P2860
P1476
Targeting Abeta and tau in Alzheimer's disease, an early interim report
@en
P2093
Jada Lewis
Todd E Golde
P2860
P304
P356
10.1016/J.EXPNEUROL.2009.07.035
P407
P577
2009-08-27T00:00:00Z